Biotech VCs Aren't Catching Silicon Valley's Latest Fever
This article was originally published in The Pink Sheet Daily
Executive Summary
Tech and Internet startups are hot once again, but the biotech sector has been left behind. At a conference in the San Francisco Bay area this week, VCs discussed whether building companies is still the right thing to do.
You may also be interested in...
Biotechs Need To Be More Differentiated To Succeed, E&Y Reports
The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.